Last updated: September 8, 2026
Pooled plasma (human), solvent/detergent treated is marketed in the United States primarily as Octaplas and OctaplasLG by Octapharma AG. The product is a pathogen-reduced, pooled human plasma replacement used for patients with multiple coagulation-factor deficiencies, including urgent reversal of warfarin-associated anticoagulation when a four-factor prothrombin complex concentrate is unavailable or inappropriate. Its commercial trajectory depends more on plasma supply, hospital adoption, reimbursement and competitor capacity than on conventional small-molecule patent exclusivity.
What is pooled plasma (human), solvent/detergent treated?
Pooled plasma is manufactured from donations from multiple human plasma sources. Solvent/detergent treatment inactivates enveloped viruses by disrupting their lipid membranes. The manufacturing process is followed by removal of the treatment agents, filtration, testing and freezing.
Octaplas and OctaplasLG are not ordinary fresh-frozen plasma. They are standardized pooled plasma products with controlled levels of coagulation proteins and lower donor-to-donor variability. The products retain clinically relevant coagulation factors, including fibrinogen, factor VIII, factor V, factor VII, factor IX, factor X, factor XI, antithrombin III and protein C [1].
FDA-approved use and dosage form
The FDA approved Octaplas in 2013 for replacement of multiple coagulation factors in patients with acquired deficiencies caused by liver disease, disseminated intravascular coagulation or dilutional coagulopathy, and for patients with congenital deficiencies when a specific factor concentrate is unavailable [2].
OctaplasLG is supplied as a frozen intravenous product in nominal 200 mL and 500 mL presentations, subject to the applicable U.S. label and packaging configuration. Administration requires thawing and infusion in a hospital or comparable acute-care setting.
| Product attribute |
Commercial description |
| Active product |
Pooled human plasma |
| Processing |
Solvent/detergent treatment and filtration |
| U.S. commercial product |
Octaplas / OctaplasLG |
| Sponsor and manufacturer |
Octapharma AG and related Octapharma entities |
| Regulatory pathway |
Biologics license application |
| Main setting |
Hospitals and acute-care facilities |
| Primary clinical role |
Replacement of multiple coagulation factors |
| Storage |
Frozen, with controlled thawing before use |
| Main competitors |
Fresh-frozen plasma, pathogen-reduced plasma, four-factor PCC and targeted coagulation-factor concentrates |
What is the FDA regulatory status of Octaplas and OctaplasLG?
Octaplas received FDA approval in December 2013 under BLA 125109. FDA records identify the product as pooled human plasma treated with solvent and detergent [2]. The approval established a U.S. regulatory framework for a standardized pathogen-reduced plasma product rather than a conventional donor-specific fresh-frozen plasma unit.
OctaplasLG is the current U.S. commercial presentation associated with the Octaplas platform. The regulatory value of the product rests on manufacturing controls, donor screening, infectious-disease testing, pooling procedures and process validation. Those requirements create barriers that are more difficult to replicate than a conventional chemical formulation.
The product is subject to biologics manufacturing requirements, pharmacovigilance, lot release controls and inspections. The manufacturing site, donor network and quality system are material commercial assets.
What patents protect pooled plasma (human), solvent/detergent treated?
The principal protection for pooled plasma is manufacturing and regulatory protection rather than a broad composition-of-matter patent.
Publicly available product information does not establish a conventional, high-value U.S. composition patent covering plasma itself. Human plasma cannot be protected as a new chemical entity. Any patent position is more likely to concern:
- solvent/detergent treatment conditions;
- pathogen-inactivation process parameters;
- removal of solvent and detergent residues;
- filtration and virus-clearance methods;
- pooling, standardization and storage;
- container or thawing systems;
- formulations that preserve coagulation-factor activity;
- manufacturing quality controls.
Patent rights in this area may be assigned to Octapharma or related entities and may differ by jurisdiction. The commercial barrier is not limited to patent expiration. A competing manufacturer would need FDA authorization, a compliant plasma-donor network, validated pathogen-reduction processes and reliable hospital distribution.
Is Octaplas listed in the Orange Book?
Octaplas is regulated as a biologic under a BLA, not as a conventional small-molecule drug approved through an NDA. The Orange Book is therefore not the central source for its exclusivity or patent status.
The relevant regulatory framework is the Purple Book and the BLA approval record. A follow-on manufacturer would face the biologics approval pathway, but the legal pathway differs from a conventional ANDA Paragraph IV challenge.
When does pooled plasma lose exclusivity?
Pooled plasma does not have a single commercially decisive patent-expiration date comparable to a small-molecule product.
Octaplas received U.S. approval in 2013. FDA reference-product exclusivity for a biologic generally runs for four years from first licensure, while a biosimilar cannot be approved for 12 years after first licensure under the Biologics Price Competition and Innovation Act. Those periods have elapsed for the original Octaplas approval [3].
The absence of remaining reference-product exclusivity does not mean immediate generic-style entry. A competitor would still need to obtain a BLA or biosimilar approval, establish comparability or demonstrate product safety and effectiveness under the applicable pathway, and operate a qualified plasma collection and manufacturing system.
Are there Paragraph IV challenges?
A conventional Paragraph IV challenge is not the expected pathway for Octaplas because Paragraph IV litigation applies to patents listed in the Orange Book for NDA products. A competing biologic would more likely proceed through a BLA or, if legally and scientifically appropriate, a biosimilar pathway under the Public Health Service Act.
No major public U.S. Paragraph IV litigation involving Octaplas was identified in the principal product and FDA records reviewed for this analysis. The absence of Paragraph IV activity reflects the product's biologic status and manufacturing complexity.
How strong is the patent estate for pooled plasma?
The patent estate is best characterized as moderate in legal theory but strong in practical protection.
| Protection category |
Relative importance |
Commercial assessment |
| Plasma composition patent |
Low |
Plasma is a biological material, not a conventional novel molecule |
| Solvent/detergent process patents |
Medium |
Could protect specific process designs, but alternative methods may exist |
| Virus-clearance and filtration patents |
Medium to high |
Validation and process know-how can raise entry costs |
| Formulation patents |
Medium |
Relevant to stability, thawing and factor preservation |
| Manufacturing know-how |
High |
Difficult to reproduce from public patent disclosures alone |
| Donor supply network |
High |
Capacity and quality controls constrain supply |
| Regulatory history |
High |
Established lot consistency and safety profile support hospital adoption |
| Distribution and contracting |
Medium to high |
Hospital and blood-bank relationships affect share |
The strongest protection is cumulative. Even if a particular patent expires, the competitor still faces a long validation cycle, capital investment and clinical/regulatory risk.
What formulations and manufacturing methods are protected?
The commercial product is supplied frozen and must be thawed before administration. Formulation and process control are important because coagulation-factor activity, sterility, residual solvent and detergent levels must remain within specifications.
Key manufacturing barriers include:
- collection and qualification of plasma donations;
- pooling under controlled conditions;
- validated solvent/detergent exposure;
- removal of treatment agents;
- viral clearance and filtration;
- control of coagulation-factor concentrations;
- low-temperature storage and transport;
- lot testing and release.
These requirements limit the ability of a standard generic-drug manufacturer to enter the market. A competitor would need access to plasma and specialized biologics infrastructure.
How does Octaplas compare with fresh-frozen plasma and four-factor PCC?
The principal competitive question is clinical substitution rather than generic substitution.
| Attribute |
Octaplas |
Fresh-frozen plasma |
Four-factor PCC |
| Product type |
Pooled, solvent/detergent-treated plasma |
Individual-donor plasma |
Concentrated coagulation factors |
| Standardization |
Higher |
Lower |
High |
| Pathogen-reduction profile |
Solvent/detergent and validated controls |
Donor screening and testing; varies by product |
Manufacturing controls |
| Volume required |
Plasma-level volume |
Plasma-level volume |
Lower volume |
| Main use |
Multiple-factor replacement |
Broad plasma replacement |
Rapid warfarin reversal and selected indications |
| Administration |
Intravenous |
Intravenous |
Intravenous |
| Hospital logistics |
Frozen product and thawing |
Frozen product and thawing |
Concentrate reconstitution |
| Main limitation |
Cost and plasma dependence |
Variability, volume and thawing |
Cost, thrombosis concerns and narrower use |
Four-factor PCC is a major competitive threat in urgent warfarin reversal because it provides concentrated factors in a smaller volume and can be administered rapidly. Octaplas remains relevant when multiple coagulation factors require replacement, when plasma is clinically preferred, or when institutional protocols favor pathogen-reduced pooled plasma.
Fresh-frozen plasma remains the largest practical substitute in many hospitals. Its lower acquisition cost and established blood-bank infrastructure can constrain Octaplas pricing.
What drives market demand for pooled plasma?
Demand is tied to acute-care utilization rather than chronic outpatient therapy. The main demand drivers are:
- cardiac and vascular surgery;
- liver transplantation and advanced liver disease;
- trauma and massive transfusion;
- disseminated intravascular coagulation;
- complex bleeding-management protocols;
- anticoagulant reversal;
- shortages of conventional plasma;
- institutional preference for standardized pathogen-reduced products.
The market is sensitive to blood-product supply disruptions. Plasma collection levels, donor recruitment, infectious-disease events, transportation capacity and hospital procedure volumes can affect demand and pricing.
Clinical guidelines also influence utilization. Overuse of plasma for mildly abnormal coagulation tests can reduce demand, while restrictive transfusion policies can shift use toward targeted concentrates or reduce plasma volume per patient.
What is the financial trajectory for Octaplas?
Octapharma does not generally disclose Octaplas revenue as a standalone product line in the manner of a public pharmaceutical company reporting product-level sales. A precise product revenue series is therefore not publicly established.
The likely financial profile is a specialized hospital biologics business with the following characteristics:
| Financial factor |
Effect on trajectory |
| Unit price |
Supports attractive revenue per administration relative to standard plasma |
| Volume growth |
Depends on hospital adoption and acute-care procedure volume |
| Plasma acquisition |
Creates major variable-cost exposure |
| Manufacturing |
Requires specialized, capital-intensive facilities |
| Gross margin |
Sensitive to donor-plasma cost, yield, testing and logistics |
| Competition |
Fresh-frozen plasma and PCC constrain pricing |
| Reimbursement |
Hospital budgets and blood-bank payment structures determine uptake |
| Supply reliability |
Shortages can improve demand but increase cost and service pressure |
| Product concentration |
Portfolio diversification reduces dependence on one product |
Octapharma's broader business is privately held, so external investors lack the quarterly product-level transparency available for publicly traded pharmaceutical companies. The product's financial trajectory is best assessed through sales growth disclosures, hospital contracting, manufacturing expansion, plasma-collection capacity and competitive tender outcomes rather than through a public revenue model.
Revenue exposure
Octaplas revenue is exposed to hospital blood-product budgets and procedure volumes. It is less exposed to retail pharmacy demand and direct-to-consumer pricing. The commercial model is therefore closer to a hospital-supplied specialty biologic than to a conventional branded prescription medicine.
Margin pressure can arise from:
- higher donor compensation and plasma-collection costs;
- lower manufacturing yield;
- increased testing and quality-control costs;
- cold-chain expenses;
- hospital purchasing pressure;
- substitution by PCC;
- lower use of plasma in restrictive transfusion protocols.
A supply shortage can support utilization and pricing in the short term, but sustained shortages can damage hospital confidence and encourage substitution.
Which companies are challenging the product?
Competition is fragmented. The relevant competitors include suppliers of fresh-frozen plasma, pathogen-reduced plasma and concentrated coagulation products.
Potential competitive groups include:
- Octapharma, through Octaplas;
- blood-establishment and transfusion-medicine suppliers offering conventional or pathogen-reduced plasma;
- CSL Behring, primarily through plasma-derived and coagulation products;
- Takeda, through selected plasma-derived therapies;
- Grifols, through plasma-derived products and blood-management activities;
- Sanofi and other manufacturers competing in coagulation-factor replacement and anticoagulant reversal.
The closest substitute depends on the indication. Fresh-frozen plasma is the closest product substitute. Four-factor PCC is the strongest alternative for urgent warfarin reversal. Recombinant or purified factor products compete where a specific deficiency can be identified.
What patent litigation and settlement risks exist?
No major public patent litigation or settlement involving Octaplas was identified in the principal U.S. regulatory and product records reviewed. The litigation risk is more likely to arise from:
- process-patent disputes;
- trade-secret claims involving plasma treatment or filtration;
- biosimilar or follow-on biologic patent litigation;
- product-liability claims;
- donor-supply and manufacturing disputes;
- hospital contracting and distribution arrangements.
A future follow-on biologic entrant could trigger patent litigation over manufacturing methods even if the plasma product itself is not protected by a composition patent. Settlement economics would depend on the entrant's ability to secure plasma supply and FDA approval, not only on the nominal patent term.
What generic launch scenarios exist?
Scenario 1: No near-term direct substitute
Octaplas retains share because manufacturing barriers, hospital qualification requirements and limited competitor capacity deter entry. Pricing remains stable, subject to hospital contracting.
Scenario 2: Follow-on pathogen-reduced plasma
A competing manufacturer obtains FDA authorization for a comparable pooled plasma product. Price competition develops first in large hospital systems and group purchasing organizations.
Scenario 3: Expanded PCC substitution
Hospitals increase use of four-factor PCC for urgent anticoagulant reversal. Octaplas demand shifts toward liver disease, surgery, trauma and broad factor replacement.
Scenario 4: Plasma supply disruption
Collection constraints or regulatory events reduce supply. Available product receives stronger demand, but cost inflation and allocation risk increase.
Scenario 5: Conventional plasma remains dominant
Hospitals continue using fresh-frozen plasma because of lower cost, existing inventory systems and clinician familiarity. Octaplas remains a premium, differentiated product.
What is the geographic coverage?
Octaplas is marketed internationally, but regulatory status, branding, labeling and reimbursement vary by country. The product's geographic expansion depends on:
- local biologics approval;
- national blood-product rules;
- plasma-donor standards;
- hospital procurement;
- reimbursement;
- cold-chain infrastructure;
- local competitors.
The United States is commercially important because of its large hospital market and demand for standardized plasma products. Europe has established transfusion systems and national blood authorities, which can create both market access opportunities and procurement barriers.
Key Takeaways
- Pooled plasma (human), solvent/detergent treated is primarily commercialized in the United States as Octaplas or OctaplasLG.
- Its strongest competitive advantages are standardized pooled plasma, pathogen-reduction processing, validated manufacturing and supply reliability.
- It does not have the typical Orange Book and Paragraph IV profile of a small-molecule drug.
- The original biologic exclusivity periods have elapsed, but practical entry barriers remain high.
- No publicly established standalone Octaplas revenue series is available because Octapharma is privately held and does not routinely disclose product-level sales.
- Fresh-frozen plasma is the closest substitute; four-factor PCC is the main competitive alternative in urgent warfarin reversal.
- Manufacturing know-how, plasma supply and regulatory validation are more important than a single composition-of-matter patent.
- The most credible commercial risks are hospital price pressure, PCC substitution, plasma-supply constraints and entry by another pathogen-reduced plasma supplier.
FAQs About Pooled Plasma (Human), Solvent/Detergent Treated
Is Octaplas a biosimilar?
No. Octaplas is an approved pooled human plasma biologic. It is not a biosimilar to a monoclonal antibody or other reference biologic.
Does Octaplas replace fresh-frozen plasma?
It can replace fresh-frozen plasma in clinically appropriate settings requiring multiple coagulation-factor replacement, but product selection depends on indication, hospital protocol, availability and physician judgment.
Is Octaplas used for hemophilia?
Octaplas is not a preferred substitute for a specific factor concentrate when the deficient factor is known and an approved concentrate is available.
Can a generic drug company manufacture Octaplas?
A conventional generic-drug company cannot rely on an ANDA to copy Octaplas. It would need an applicable biologics regulatory pathway and validated plasma, pathogen-reduction and manufacturing capabilities.
What is the largest long-term commercial threat to Octaplas?
The largest long-term threat is substitution by four-factor PCC and other targeted coagulation products, combined with competition from conventional or newly approved pathogen-reduced plasma products.
References
-
Octapharma AG. (2023). OctaplasLG prescribing information. U.S. Food and Drug Administration.
-
U.S. Food and Drug Administration. (2013). Octaplas approval letter and biologics license application BLA 125109. Center for Biologics Evaluation and Research.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/
